40 related articles for article (PubMed ID: 16136374)
1. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer.
Homesley HD; Meltzer NP; Nieves L; Vaccarello L; Lowendowski GS; Elbendary AA
Int J Clin Oncol; 2008 Feb; 13(1):62-5. PubMed ID: 18307021
[TBL] [Abstract][Full Text] [Related]
3. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
4. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
Akizuki S; Katsumata N; Yamanaka Y; Andoh M; Fujiwara Y; Watanabe T
Int J Clin Oncol; 2005 Aug; 10(4):272-5. PubMed ID: 16136374
[TBL] [Abstract][Full Text] [Related]
6. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Dunder I; Berker B; Atabekoglu C; Bilgin T
Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
[TBL] [Abstract][Full Text] [Related]
8. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Vandenput I; Vergote I; Neven P; Amant F
Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Fleming GF; Brunetto VL; Cella D; Look KY; Reid GC; Munkarah AR; Kline R; Burger RA; Goodman A; Burks RT
J Clin Oncol; 2004 Jun; 22(11):2159-66. PubMed ID: 15169803
[TBL] [Abstract][Full Text] [Related]
12. Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Nishio S; Ota S; Sugiyama T; Matsuo G; Kawagoe H; Kumagai S; Ushijima K; Nishida T; Kamura T
Int J Clin Oncol; 2003 Feb; 8(1):45-8. PubMed ID: 12601542
[TBL] [Abstract][Full Text] [Related]
13. [Latest information of therapeutic approach for endometrial cancer].
Katsumata N; Yamanaka Y; Kitagawa R
Gan To Kagaku Ryoho; 2002 Aug; 29(8):1371-6. PubMed ID: 12214463
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.
Markman M; Hall J; Spitz D; Weiner S; Carson L; Van Le L; Baker M
J Clin Oncol; 2002 May; 20(9):2365-9. PubMed ID: 11981009
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]